Orchard Therapeutics is a biopharmaceutical company pioneering in the development and commercialization of transformative therapies for individuals with severe genetic diseases. The company is focusing on Hematopoietic Stem Cell (HSC) gene therapy, aiming to address unmet medical needs by offering potentially curative treatment options. With a commitment to improving lives significantly impacted by genetic conditions like metachromatic leukodystrophy, Orchard Therapeutics strives to change the treatment paradigm through innovative scientific research and dedication to patients' well-being.